
HONG KONG, Feb 11, 2020 - (ACN Newswire) - Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule...
Read more: Aptorum Group Announces Further Positive Data for its ALS-4 Small Molecule Anti-virulence...